Oxalate crystal aggregation pathway

The "Oxalate crystal aggregation pathway" describes the sequence of physicochemical and cellular events leading to the formation and aggregation of calcium oxalate crystals in urine, which is the primary component of most human kidney stones. The pathway involves the supersaturation of urine with calcium and oxalate ions, nucleation of amorphous precursors, growth into detectable crystals, and subsequent aggregation into larger particles. Amorphous calcium phosphate and oxalate precursors form coaggregates that serve as templates for calcium oxalate monohydrate (COM) nucleation, eventually creating large, clinically relevant stones that can injure renal epithelial cells and obstruct the urinary tract. Aggregation depends on factors including urine composition, pH, presence of inhibitors like citrate, and the shape and surface characteristics of the crystals. Although no single molecule can be identified as the "target," the pathway as a whole is considered a legitimate site for therapeutic intervention, mostly through agents that alter urine chemistry to inhibit aggregation rather than direct molecular inhibition.

Other names

Oxalate crystallization pathwayCalcium oxalate stone formation pathwayOxalate biomineralization process

Inhibition of nucleation and aggregation of calcium oxalate crystals (e.g., citrate binds to calcium, preventing aggregation); Modification of urine composition to favor dissolution or non-aggregation